Literature DB >> 22418996

Presymptomatic genetic testing in CADASIL.

S Reyes1, A Kurtz, D Hervé, E Tournier-Lasserve, H Chabriat.   

Abstract

Genetic counselling has been poorly investigated in cerebrovascular diseases. Characteristics, motivations and long-term outcome of presymptomatic tests (PT) in subjects at risk of CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) were investigated at the National Centre for Rare Vascular Diseases of the Brain and/or Retina (CERVCO). Sociodemographic, motivational and psychological variables were collected between 2003 and 2010 for PT applicants. Multidisciplinary consultations (with a geneticist, neurologist and psychologist) were proposed over a 6 month period. When PT showed a deleterious mutation of the NOTCH3 gene, cognitive performances, mood, autonomy and quality of life were also assessed. Over 7 years, only 33 subjects asked for a PT of CADASIL. They were predominantly women, lived as a couple, had children and were of high sociocultural level. The dropout rate after the first step of the procedure was 63%. The characteristics of the 11 subjects who reached the end of the procedure did not differ from the 22 who dropped out. Six were carriers of the deleterious mutation and were still asymptomatic after a mean follow-up of 19 months. They did not experience any particular negative event and all of them indicated a high score of overall quality of life. Indeed, two carriers gave birth to their first child. These initial data in CADASIL show that PT is rarely requested and that there is a high dropout rate. Our study also highlights that a multidisciplinary and multistep procedure in genetic counselling testing appears useful to obtain minimal harmful consequences of genetic testing.

Entities:  

Mesh:

Year:  2012        PMID: 22418996     DOI: 10.1007/s00415-012-6468-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease.

Authors:  A Tibben; M Stevens; G M de Wert; M F Niermeijer; C M van Duijn; J C van Swieten
Journal:  J Med Genet       Date:  1997-01       Impact factor: 6.318

Review 2.  New information on the genetics of stroke.

Authors:  James F Meschia
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 3.  To know or not to know: a review of behaviour and suicidal ideation in preclinical Huntington's disease.

Authors:  Tarja-Brita Robins Wahlin
Journal:  Patient Educ Couns       Date:  2006-09-26

Review 4.  Genetics and genomics of stroke: novel approaches.

Authors:  Alison E Baird
Journal:  J Am Coll Cardiol       Date:  2010-07-20       Impact factor: 24.094

5.  Psychosocial impact of screening for intracranial aneurysms in relatives with familial subarachnoid hemorrhage.

Authors:  M J H Wermer; I C van der Schaaf; P Van Nunen; P M M Bossuyt; C S Anderson; G J E Rinkel
Journal:  Stroke       Date:  2005-03-03       Impact factor: 7.914

6.  International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease.

Authors: 
Journal:  J Med Genet       Date:  1994-07       Impact factor: 6.318

7.  [Vasculitis and hereditary small vessel diseases].

Authors:  C Opherk; N Peters; M Dichgans
Journal:  Internist (Berl)       Date:  2009-11       Impact factor: 0.743

Review 8.  Cadasil.

Authors:  Hugues Chabriat; Anne Joutel; Martin Dichgans; Elizabeth Tournier-Lasserve; Marie-Germaine Bousser
Journal:  Lancet Neurol       Date:  2009-07       Impact factor: 44.182

9.  Ethical considerations of genetic presymptomatic testing for Huntington's disease.

Authors:  Alberto Coustasse; Alicia Pekar; Andrew Sikula; Sue Lurie
Journal:  J Hosp Mark Public Relations       Date:  2009 Jul-Dec

10.  Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL.

Authors:  A Viswanathan; A Gschwendtner; J-P Guichard; F Buffon; R Cumurciuc; M O'Sullivan; M Holtmannspötter; C Pachai; M-G Bousser; M Dichgans; H Chabriat
Journal:  Neurology       Date:  2007-07-10       Impact factor: 9.910

View more
  5 in total

1.  Mutational screening of NOTCH3 gene reveals two novel mutations: complexity of CADASIL diagnosis.

Authors:  Lorena Mosca; Francesca Rivieri; Raffaella Tanel; Aldo Bonfante; Alessandro Burlina; Emanuela Manfredini; Paola Primignani; Giovanni P Gesu; Alessandro Marocchi; Silvana Penco
Journal:  J Mol Neurosci       Date:  2014-05-10       Impact factor: 3.444

Review 2.  Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects.

Authors:  Ilaria Di Donato; Silvia Bianchi; Nicola De Stefano; Martin Dichgans; Maria Teresa Dotti; Marco Duering; Eric Jouvent; Amos D Korczyn; Saskia A J Lesnik-Oberstein; Alessandro Malandrini; Hugh S Markus; Leonardo Pantoni; Silvana Penco; Alessandra Rufa; Osman Sinanović; Dragan Stojanov; Antonio Federico
Journal:  BMC Med       Date:  2017-02-24       Impact factor: 8.775

3.  Vasoreactivity in CADASIL: Comparison to structural MRI and neuropsychology.

Authors:  Fiona C Moreton; Breda Cullen; Christian Delles; Celestine Santosh; Rosario L Gonzalez; Krishna Dani; Keith W Muir
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-24       Impact factor: 6.200

4.  Updates on Prevention of Hemorrhagic and Lacunar Strokes.

Authors:  Hsin-Hsi Tsai; Jong S Kim; Eric Jouvent; M Edip Gurol
Journal:  J Stroke       Date:  2018-05-31       Impact factor: 6.967

Review 5.  Genetic counseling and testing practices for late-onset neurodegenerative disease: a systematic review.

Authors:  Ashley Crook; Chris Jacobs; Toby Newton-John; Rosie O'Shea; Alison McEwen
Journal:  J Neurol       Date:  2021-03-01       Impact factor: 6.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.